Advancing Lymphoma Care: ctDNA Applications in Risk Stratification and Treatment Monitoring

Can ctDNA spot relapse early and justify treating "molecular" lymphoma? Alpha-3 tests allo CAR T, weighing toxicity, MRD clearance, survival.

Alpha-3 sparks debate on treating ctDNA-positive lymphoma early—can allo CAR T or bispecifics erase MRD without excess toxicity?

Can ctDNA and interim PET guide shorter DLBCL chemo? Experts weigh de-escalation to reduce toxicity and urge randomized trials.

Can ctDNA and interim PET guide shorter DLBCL chemo? Experts weigh de-escalation to cut toxicity, urging randomized trials.

How ctDNA trends after CAR T reshape relapse monitoring, pairing MRD blood tests with PET scans to gauge response and relapse risk.

Experts weigh ctDNA blood tests in lymphoma, highlighting phased-variant assays for end-of-therapy sensitivity and future tech advances.